## Joanna Sobiak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3719079/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Pharmacokinetics of Enteric-Coated Mycophenolate Sodium Metabolites in Patients Over 60 Years Old Within the First Year After Renal Transplantation. Transplantation Proceedings, 2021, 53, 1001-1004.	0.3	2
2	The Evaluation of Multiple Linear Regression–Based Limited Sampling Strategies for Mycophenolic Acid in Children with Nephrotic Syndrome. Molecules, 2021, 26, 3723.	1.7	7
3	A Systematic Review of Multiple Linear Regression-Based Limited Sampling Strategies for Mycophenolic Acid Area Under the Concentration–Time Curve Estimation. European Journal of Drug Metabolism and Pharmacokinetics, 2021, 46, 721-742.	0.6	10
4	Recent Advances in Therapeutic Drug Monitoring of Voriconazole, Mycophenolic Acid, and Vancomycin: A Literature Review of Pediatric Studies. Pharmaceutics, 2021, 13, 1991.	2.0	10
5	The Application of Inosine 5′-Monophosphate Dehydrogenase Activity Determination in Peripheral Blood Mononuclear Cells for Monitoring Mycophenolate Mofetil Therapy in Children with Nephrotic Syndrome. Pharmaceuticals, 2020, 13, 200.	1.7	6
6	Limited sampling strategy to predict mycophenolic acid area under the curve in pediatric patients with nephrotic syndrome: a retrospective cohort study. European Journal of Clinical Pharmacology, 2019, 75, 1249-1259.	0.8	9
7	Thiopurine methyltransferase activity in children with acute myeloid leukemia. Oncology Letters, 2018, 16, 4699-4706.	0.8	3
8	Development of a Limited Sampling Strategy for the Estimation of Exposure to High-Dose Etoposide After Intravenous Infusion in Pediatric Patients. Therapeutic Drug Monitoring, 2017, 39, 138-144.	1.0	2
9	SP700LIMITED SAMPLING STRATEGY FOR THE AREA UNDER CONCENTRATION-TIME CURVE ESTIMATION IN CHILDREN WITH NEPHROTIC SYNDROME TREATED WITH MYCOPHENOLATE MOFETIL. Nephrology Dialysis Transplantation, 2016, 31, i330-i330.	0.4	0
10	Pharmacokinetics of mycophenolate sodium co-administered with tacrolimus in the first year after renal transplantation. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 331-338.	0.6	8
11	Monitoring of mycophenolate mofetil metabolites in children with nephrotic syndrome and the proposed novel target values of pharmacokinetic parameters. European Journal of Pharmaceutical Sciences, 2015, 77, 189-196.	1.9	25
12	Clinical and In Vitro Studies on Impact of High-Dose Etoposide Pharmacokinetics Prior Allogeneic Hematopoietic Stem Cell Transplantation for Childhood Acute Lymphoblastic Leukemia on the Risk of Post-Transplant Leukemia Relapse. Archivum Immunologiae Et Therapiae Experimentalis, 2015, 63, 385-395.	1.0	2
13	Development and Validation of Limited Sampling Strategies for the Estimation of Mycophenolic Acid Area Under the Curve in Adult Kidney and Liver Transplant Recipients Receiving Concomitant Enteric-Coated Mycophenolate Sodium and Tacrolimus. Therapeutic Drug Monitoring, 2013, 35, 760-769.	1.0	18
14	Effect of mycophenolate mofetil on hematological side effects incidence in renal transplant recipients. Clinical Transplantation, 2013, 27, E407-14.	0.8	20
15	Effect of clinical condition and mycophenolate mofetil on plasma retinol, α-tocopherol and β-carotene in renal transplant recipients. Archives of Medical Science, 2012, 2, 256-262.	0.4	3
16	Pharmacokinetics of mycophenolic acid and its phenyl glucuronide metabolite in kidney transplant recipients with renal impairment. Archives of Medical Science, 2012, 1, 88-96.	0.4	15
17	Effect of Mycophenolate Mofetil on Plasma Bioelements in Renal Transplant Recipients. Biological Trace Element Research, 2012, 145, 136-143.	1.9	9
18	Pharmacokinetics of highâ€dose etoposide administered in combination with fractionated totalâ€body irradiation as conditioning for allogeneic hematopoietic stem cell transplantation in children with acute lymphoblastic leukemia. Pediatric Transplantation, 2011, 15, 96-102.	0.5	6